Uracil mustard revisited

Cancer

Volumn 85, Issue 10, 1999, Pages 2265-2272

  Kennedy, B J ^a   Torkelson, Jane L ^a   Torlakovic, Emina ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic lymphatic leukemia; Cost; Lymphoma; Thrombocytosis; Uracil mustard

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; FLUDARABINE; PREDNISOLONE; URAMUSTINE; VINCRISTINE;

ALKYLATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; URACIL MUSTARD;

EID: 0033562465     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990515)85:10<2265::AID-CNCR23>3.0.CO;2-9     Document Type: Article

References (51)

1. Greally JF, Theologides A, Kennedy BJ. Apparent chemotherapeutic cure of malignant lymphoma. Cancer 1991;27: 887-93.
2. Lyttle DA, Petering HB. 5-Bis-(2-chlor-ethyl)-aminouracil, a new antitumor agent. J Am Chem Soc 1958;80:6459.
3. Lyttle DA, Petering HB. 5-Bis-(2-chlorethyl)-aminouracil, a new antitumor agent. J Natl Cancer Inst 1959;23:153-62.
4. Evans JS, Mengel GD. Antitumor activity of 5-bis-(2-chlorethyl)-aminouracil against sarcoma 180 and Ehrlich carcinoma. Proc Soc Exp Biol Med 1958; 99:620-2.
5. Lane M, Kelly MG. The antitumor activity of uracil mustard, a new alkylating agent [abstract]. Clin Res 1959;7:46-7.
6. Lane M, Kelly MG. The antitumor activity of 5-bis-(2-chlorethyl)-aminouracil (uracil mustard). Cancer Res 1960; 20:511-7.
7. Lane M, Lipowska B, Hall TC, Colsky J. Observations on the clinical pharmacology of 5-[bis(2-chloroethyl) amino] uracil (uracil mustard; NSC-34462). Cancer Chemother Rep 1960; 9:31-6.
8. Shanbrom E, Miller S, Haar H, Opfell R. Therapeutic spectrum of uracil-mustard, a new oral antitumor drug. JAMA 1960;1974:1702-5.
9. Kennedy BJ, Theologides A. Effect of uracil mustard in leukemia and lymphoma [abstract]. Clin Res 1960;8:251.
10. Kennedy BJ, Theologides A. Effect of uracil mustard in chronic lymphatic leukemia and malignant lymphoma. Cancer Chemother Rep 1961;11:77-80.
11. Kennedy BJ, Theologides A. Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma. N Engl J Med 1961;264:790-3.
12. Theologides A, Kennedy BJ. Effect of uracil mustard in malignant lymphoma and chronic lymphatic leukemia. Minn Med 1962;45:165-8.
13. Fortuny IE, Theologides A, Kennedy BJ. Single, combined and sequential use of uracil mustard and prednisone. Minn Med 1972;55:715-6.
14. Nair KJ, Moayeri H, Mittelman A. A phase II study of fluorodopan in the treatment of advanced colorectal cancer. Cancer Treat Rep 1980;64:697-9.
15. Spurr CL, Hayes DM. Clinical observation in newer chemotherapeutic agents. South Med J 1960;53:1005-14.
16. Robertson JH. Uracil mustard in the treatment of thrombocythemia. Blood 1970;35:288-97.
17. Shamasunder HK, Gregory SA, Knospe WH. Uracil mustard in the treatment of thrombocytosis. JAMA 1980;244:1454-5.
18. Kennedy BJ, Yarbro JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA 1966;195: 1038-43.
19. Kennedy BJ, Gilbertsen AS. Increased erythropoiesis induced by androgenic hormone therapy. N Engl J Med 1957; 256:719-26.
20. Kennedy BJ. Androgenic hormone therapy in lymphatic leukemia. JAMA 1964;190:1130-2.
21. Kennedy BJ. The use of androgen in the treatment of diseases of the hematopoietic system. Pergamon Press Pharmac Ther 1977;2:39-56.
22. Weiss RB, Brunning RD, Kennedy BJ. Lymphosarcoma terminating in acute myelogenous leukemia. Cancer 1972;30: 1275-8.
23. Rai KR, Sawitsky FL, Cronkite EP, Chanana AP, Levy RN, Pasternack BS. Clinical staging of chronic lymphatic leukemia. Blood 1975;46:219-34.
24. Longo DL. The REAL classifications of lymphoid neoplasms: one clinician's view. Principles Practice Oncol Updates 1995; 9:1-12.
25. Cheson BD. New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas. Semin Oncol 1993;20(Suppl 5):96-110.
26. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(Suppl 5): 75-88.
27. Gold GL, Salvin LG, Shnider BI. A comparative study with three alkylating agents: mechlorethamine, cyclophosphamide, and uracil mustard. Cancer Chemother Rep 1962;16: 417-25.
28. Williams HM. Clinical evaluation of uracil mustard. Cancer Chemother Rep 1963;32:73-6.
29. Schumacker HR, O'Connell JP. The intravenous use of uracil mustard (U-8344). Cancer 1963;16:345-9.
30. Gold GL, Shnider BI, Salvin LG, Schneiderman MA, Colsky J, Owens AH Jr., et al. The use of mechlorethamine, cyclophosphamide, and uracil mustard in neoplastic disease: a cooperative study. J Clin Pharm J New Drugs 1970;10:110-20.
31. Dana BS, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644-51.
32. Solal-Céligny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-9.
33. Cazin B, Divine M, Couillet D, Caulier MT, Fenaux P, Morel P. Long-term outcome after fludarabine (FAMP) in 133 patients with advanced B-cell chronic lymphoid malignancies [Abstract 1382]. Blood 1995;86(Suppl 1):349a.
34. Hochster H, Oken M, Bennett J, Wolf B, Gordon L, Raphael B, et al. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL)-ECOG 1491 [Abstract 1517]. Blood 1994;84:(Suppl 1):383a.
35. Rozman C, Montserrat E. Chronic lymphatic leukemia. N Engl J Med 1995;333:1052-7.
36. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphatic leukemia. Ann Intern Med 1996;124:311-5.
37. Rai KR, Peterson B, Kolitz J, Elias L, Shepherd L, Nines J, et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia: a randomized intergroup study [Abstract 2414]. Blood 1995;86(Suppl 1):607a.
38. Tallman MS, Hakimian D, Zanzig C, Hogan DK, Rademaker A, Rose E, et al. Cladribine in the treatment of relapsed or refractory chronic lymphatic leukemia. Clin Oncol 1995;13: 983-8.
39. Frommeyer WB. Comparison of cyclophosphamide (Cytoxan) and uracil mustard (U-8344) in chronic granulocytic leukemia. Cancer 1964;17:288-96.
40. Herrmann RP, Dougan L, Holt JA, Jackson JM, Matthews ML, Nelson AJ, et al. Chronic granulocytic leukaemia: comparison of uracil mustard and busulphan. Med J Aust 1972; 1:789-91.
41. Rushing D, Goldman A, Gibbs G, Home R, Kennedy BJ. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol 1982;5:307-13.
42. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
43. Emilia G, Sacchi S, Temperani P, Longo R, Vecchi A. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993;9:423-6.
44. Cardamone JM, Kimmerle RI, Marshall EY. Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. Am J Med 1974;57:836-42.
45. Reimer RR, Hoover R, Fraumeni JF Jr., Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977;297:177-81.
46. Ratti M, Ohio R, Casciaro S, Rattenni S, Boccaccio P. Acute promyelocytic leukaemia developing in essential thrombocythaemia: blastic crisis or secondary acute leukaemia? Case report. Haematologica 1984;69:330-5.
47. Toh BT, Gregory SA, Knospe WH. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. Am J Hematol 1988;28:58-60.
48. Sedlacek SM, Curtis JL, Weintraub J, Levin J. Essential thrombocythemia and leukemic transformation. Medicine 1986;65:353-64.
49. Petering HG, Buskirk HH, Musser EA, Evans JS. A comparison of the biological activity of uracil mustard and Dopan. Cancer Chemother Rep 1963;27:1-10.
50. Zubrod CG, Burchenal J, Wasserman L, Selawry OS, Carter S. Cancer chemotherapy mission's visit to Soviet Union. JAMA 1972;222:496-7.
51. Smith OP, Hoffbrand AV, Buckeley C. Fludarabine and psoriasis. N Engl J Med 1994;330:1540-1.